Saturday 17 October 2026
Export GRFS’s income statement to Excel — free account
Grifols, S.A.
GRFS Healthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue grew 5.76%, EPS grew 466.9%, free cash flow grew 300.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
7.64
0.10
+1.33%
Follow GRFS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 8.88 | 10.35 | 24.51 |
+8 more quarters Free account |
P/S ratio |
— | 0.63 | 0.75 | 0.84 | |
P/FCF ratio |
— | 9.06 | 9.85 | 14.04 | |
P/Operating CF |
— | 42.39 | 13.70 | 17.58 | |
P/B ratio |
— | 0.59 | 0.74 | 0.78 | |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.00 | |
EV/Sales |
— | 1.84 | 1.91 | 2.10 | |
EV/EBITDA |
— | 8.23 | 8.51 | 9.61 | |
EV/Operating CF |
— | 13.57 | 13.76 | 16.37 | |
EV/FCF |
— | 26.37 | 25.24 | 35.25 | |
Quick Ratio |
0.70 | 0.76 | 0.80 | 0.85 | |
Current Ratio |
2.37 | 2.47 | 2.51 | 2.48 | |
Net Debt/EBITDA |
0.00 | 25.10 | 22.27 | 19.13 | |
Debt/Assets |
46.57% | 48.16% | 48.92% | 48.80% | |
Debt/Equity |
1.17 | 1.23 | 1.27 | 1.28 | |
Asset Turnover |
0.00 | 0.38 | 0.38 | 0.35 | |
Operating CF/Net income |
0.00 | 1.51 | 4.20 | 2.63 | |
Capex/Depreciation |
(1.09) | (0.87) | (1.02) | (1.02) | |
Interest Coverage |
— | 1.81 | 1.68 | 2.27 | |
Research and Development Expense of Revenue |
— | 5.29% | 6.87% | 5.20% | |
Selling, General and Administrative Expense of Revenue |
— | 16.53% | 14.10% | 15.28% | |
Intangible Assets out of Total Assets |
0.49 | 0.53 | 0.49 | 0.53 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
— | (1.50) | (1.25) | (1.19) | |
Graham Number |
— | 0.00 | 16.03 | 0.00 | |
Earnings Yield |
— | 11.26% | 9.66% | 4.08% | |
Free Cash Flow Yield |
— | 11.04% | 10.15% | 7.12% | |
Revenue per Share |
— | 0.00 | 3.39 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.68 | 0.00 | |
Capex per Share |
0.00 | 0.00 | (0.20) | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.48 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 1.43 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 12.64 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 12.64 | 0.00 | |
Free Cash Flow |
128.91 | 23.41 | 327.96 | 259.44 | |
Working Capital |
3,568.33 | 3,663.35 | 3,456.43 | 3,733.38 | |
Capital Expenditures |
(134.18) | (105.34) | (136.42) | (130.72) | |
Net Current Asset Value |
(7,912.18) | (8,165.88) | (7,959.40) | (8,132.08) | |
EV/EBIT |
— | 11.21 | 11.59 | 11.94 | |
Capex to Sales |
0.00 | 0.05 | 0.06 | 0.06 | |
Price to Operating Income |
— | 3.85 | 4.52 | 4.76 | |
| Other line items | |||||
Average Receivables |
997.85 | 1,031.48 | 960.73 | 1,037.27 | |
Average Payables |
968.46 | — | 865.12 | — | |
Average Inventory |
3,929.75 | 3,880.29 | 3,764.44 | 3,907.92 | |
Average Assets |
22,899.16 | 22,800.10 | 22,303.03 | 23,606.37 | |
Average Common Equity |
8,951.89 | 8,960.87 | 7,242.39 | 8,878.00 |
Columns are period end dates